与Panton-Valentine leucocidin (PVL) 毒素相关的葡萄球菌性肺炎
Adrian Gillissen1,2, Daniel Räpple3, Tina Wagenknecht4
1Klinik für Pneumologie und Beatmungsmedizin, Klinikum Stuttgart Katharinenhospital, Stuttgart, Germany.
潘顿-瓦伦丁白素 (PVL) 产生金黄色葡萄球菌导致严重的入侵性疾病. 早期怀疑和及时治疗对于PVL黄金色杆菌死性肺炎至关重要,脱殖是关键的预防措施.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 毒理学 毒理学 毒理学
背景情况:
- 潘顿-瓦伦丁白素 (PVL) 是一种葡萄球菌毒素,导致中性粒细胞溶解.
- 全球范围内正在出现侵袭性社区发病的PVL产生的金黄色葡萄球菌 (S. aureus) 疾病.
- 诊断实验室并不经常对PVL进行检测,这阻碍了早期检测.
研究的目的:
- 为提供PVL S. aureus流行病学概述.
- 讨论PVL黄金色杆菌感染的抗菌治疗选择.
- 为了突出脱殖民化预防策略.
主要方法:
- 病例介绍:PVL S. aureus 死亡性肺炎.
- 对PVL S. aureus. 的当前文献的综述.
- 讨论关于抗生素对PVL表达的影响的体外发现.
主要成果:
- 黄金色杆菌可导致严重的死灰性肺炎,败血症和炎.
- 快速演变的临床表现,包括腔腔巩固和血液溶解,表明PVL S. aureus肺炎.
- 一些抗生素可能会增加PVL的表达;高剂量,基于间隔的治疗是谨慎的.
结论:
- 早期怀疑和积极的治疗对于PVL黄金色杆菌死性肺炎至关重要.
- 抗生素的选择和剂量需要仔细考虑,以避免增加PVL表达.
- 脱殖和减少生物负担是有效的预防PVL黄金色白菌动物性感染.
更多相关视频
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
07:27Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
Published on: July 12, 2018
相关概念视频
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-III
